Nano cap Neovasc (NASDAQ:NVCN) is up 27% premarket on light volume in reaction to its announcement of positive 12-year follow-up data on the Neovasc Reducer in patients with severe angina pectoris. The results were just published in the Journal of the American College of Cardiology.
At year 12, all seven patients implanted with the Reducer in 2005 reported sustained improvements in angina class versus baseline. There were no signs of strut fractures, dislocation, thrombosis or migration.
The Reducer, a device deployed like a stent, provides relief from angina symptoms by altering the blood flow in the heart's circulatory system, increasing the perfusion of oxygenated blood to ischemic (inadequate blood flow) areas of cardiac muscle. It is currently CE Mark certified.
Previously: Neovasc up 18% premarket on positive Reducer data (Oct. 3)
Subscribe for full text news in your inbox